42268 Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Psoriasis in Europe
Journal of The American Academy of Dermatology(2023)
摘要
Background: ABP 501 is the first EMA- and FDA-approved adalimumab (ADA) biosimilar for treating certain immune-mediated inflammatory diseases including psoriasis (PsO). Real-world data of its utilization are limited.
更多查看译文
关键词
adalimumab biosimilar,psoriasis,real-world
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要